Factories in China were a little louder in August, with activity expanding at the fastest pace in five months.Factories in China were a little louder in August, with activity expanding at the fastest pace in five months.

Chinese factories see strongest growth since March, PMI beats expectations

Chinese factories were a little louder in August, with activity expanding at the fastest pace in five months. A closely watched private survey, the RatingDog China General Manufacturing Purchasing Managers’ Index (PMI), compiled by S&P Global, climbed to 50.5, up from 49.5 in July and higher than analysts had forecast.

A score of 50 and above signals growth, while anything south of 50 signifies a market contraction. For Chinese manufacturers who have seen the impact of tariffs and weak local demand firsthand, the activities of August may offer a measure of relief.

However, the official PMI data released a day earlier suggests that the country’s manufacturing sector is still in the contraction zone as it stands at 49.4, a 0.1 increase from its July index.

Analysts are suggesting that manufacturing hasn’t picked up due to uncertainties in ongoing US-China trade negotiations.

RatingDog tells a different story. “Notably, the manufacturing sector is helping the recovery, but this rebound is patchy,” said Yao Yu, founder of RatingDog. “The question is whether exports can stabilize and whether domestic demand can catch up.”

New orders pile up, exports struggle

Factories reported an increase in new domestic orders, the fastest rise since March, which left production lines backed up with unfinished work. But the picture was less rosy for exports. Orders from overseas partners fell for the fifth month in a row, reflecting cautious buyers and the uncertainty swirling around US–China trade negotiations.

The effects are already being felt abroad. American retailers importing holiday products such as artificial Christmas trees and festive decorations have cut back purchases to avoid tariff costs. For US shoppers, that means higher prices and fewer options this holiday season.

Still, Chinese manufacturers were cautious about celebrating too soon. Many chose not to hire more staff, cutting jobs instead for a fifth consecutive month, a reminder that the rebound has yet to build real confidence.

Asia’s mixed picture under tariff strain

China’s improvement stands out against a gloomier backdrop elsewhere in Asia, where the weight of US tariffs continues to bear down.

In Japan, factory activity shrank for the second month in a row. The country’s PMI edged up to 49.7 in August, but export orders tumbled at the sharpest pace since early 2024 as demand weakened in China, Europe and the US.

South Korea fared no better, recording a seventh straight month of contraction with a PMI of 48.3. Even though Seoul secured a tariff cut from Washington in July, lowering duties on its exports from 25% to 15%, the data suggest that the relief has yet to reach manufacturers.

Taiwan also reported weaker factory output, while the Philippines and Indonesia managed modest growth. India, meanwhile, was the outlier: its factories expanded at the fastest pace in 17 years, powered by strong domestic demand.

Still, economists warn that Washington’s newly imposed 50% tariffs on Indian exports could quickly slow that momentum.

China’s property market, still struggling with a debt overhang and weak sales, remains another drag on growth, limiting the ability of households to spend. Without a stronger domestic consumer base, analysts fear factories will remain exposed to external shocks.

Business confidence for the year ahead rose to its highest level since March, with many factory owners betting that expansion plans and an improving global outlook could keep orders flowing.

Want your project in front of crypto’s top minds? Feature it in our next industry report, where data meets impact.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23